Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype

Drug Metabolism and Drug Interactions

Volumn 19, Issue 1, 2002, Pages 1-11

  Jann, Michael W ^a   ZumBrunnen, Troy L ^a   Kazmi, Yusuf R ^a   VanDenBerg, Chad M ^a   Desai, Hiral D ^a   Weidler, Donald J ^a   Flockhart, David A ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

CYP2C19; Fluvoxamine; Genotype; Pharmacokinetics; Phenotype

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; FLUVOXAMINE; OMEPRAZOLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ALLELE; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROSPECTIVE STUDY;

EID: 0036381764     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi.2002.19.1.1     Document Type: Conference Paper

References (24)

1. Perruca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27: 175-190.
2. Overmars H, Scherpenisse PM, Post LC. Fluvoxamine maleate: metabolism in man. Eur J Clin Pharmacokinet 1983; 8: 269-280.
3. Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand 1997; 96 (Suppl 391): 14-21.
4. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993; 45: 1211-1214.
5. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994; 55 (Suppl 12): 38-45.
6. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP 2C19 but not CYP 2D6 by fluvoxamine. Br J Clin Pharmacol 1996; 42: 518-521.
7. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-dependent inhibition of CYP 1A2, CYP 2C19 and CYP 2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-78.
8. Madsen H, Enggard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP 2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001; 69: 41-47.
9. Perucca E, Gastti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in healthy volunteers. Clin Pharmacol Ther 1994; 56: 471-476.
10. Bertilsson L. Geographical/interracial differences in polymorphism drug oxidation. Clin Pharmacokinet 1995; 29: 192-209.
11. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, Zhou HH. Pharmaco-kinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 70: 42-47.
12. Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W. Determinants of interindividual variability and extent of CYP 2D6 and CYP 1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Pharmacol 1998; 18: 198-207.
13. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP 2D6 and also by the CYP 1A2 activity. Clin Pharmacol Ther 1996; 60: 183-190.
14. Spigset O, Gransberg K, Haag S, Nortrom A, Dahlqvst R. Relationship between fluvoxamine pharmacokinetics and CYP 2D6/2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997; 52: 129-133.
15. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57: 662-669.
16. Marinac JS, Balian JD, Foxsworth JW, Willsie SK, Daus JC, Owen R, Flockhart DA. Determination of CYP 2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 1996; 60: 138-144.
17. Heim M, Meyer UA. Genotyping of poor metabolizers of debisoquine by allele specific PCR amplification. Lancet 1990; 336: 529-532.
18. Pullen RH, Fatmi AA. Determination of fluvoxamine in human plasma by high-performance liquid chromatography with fluorescene detection. J Chromatogr Biomed Applic 1992; 574: 101-107.
19. Dahl ML, Sjoqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monitor 2000; 22: 114-117.
20. Ishizaki T, Sohn DR, Kobayashi K, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monitor 1994; 16: 214-215.
21. Flockhart DA. Drug interactions and the cytochrome P450 system - the role of cytochrome P450 2C19. Clin Pharmacokinet 1995; 29 (Suppl 1): 45-52.
22. Qin XP, Xie HG, Wang W, et al. Effect of the gene dosage of CYP 2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 1999; 66: 642-646.
23. Mihara K, Suzuki A, Kondo T, et al. Effects of the CYP2D6* 10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharamcol Ther 1999; 65: 291-294.
24. Stolley PD, Strom BL. Sample size calculation for clinical pharmacology studies. Clin Pharmacol Ther 1986; 39: 489-490.